202220212020201920182017201620152014 May 16, 2022 Summary ToggleSpero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update May 11, 2022 Summary ToggleSpero Therapeutics to Present at Upcoming Investor Conferences May 09, 2022 Summary ToggleSpero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022 May 03, 2022 Summary ToggleSpero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline April 21, 2022 Summary ToggleSpero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases April 06, 2022 Summary ToggleSpero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine March 31, 2022 Summary ToggleSpero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update March 17, 2022 Summary ToggleSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022 February 16, 2022 Summary ToggleSpero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital January 19, 2022 Summary ToggleSpero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
